Dry age-related macular degeneration progresses slowly but relentlessly, resulting in meaningful loss. Most interventions have focused on watchful waiting rather than proactive support.
Photobiomodulation offers a noninvasive option that targets retinal bioenergetics and microvascular dynamics. This is why interest has moved beyond single-site pilots into system-wide adoption.
The question for scientific readers is no longer whether light can modulate retinal physiology but how to implement dosing, measurement, and safety at scale.
Authors summary: Scaling photobiomodulation for Dry AMD treatment.